NCT03604315 2026-04-15
Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF
M.D. Anderson Cancer Center
Phase 1 Recruiting
Clinical Trials
12 trialsNCT05377996 2026-04-14
A Study of XMT-1660 in Participants With Solid Tumors
Mersana Therapeutics
Phase 1 Recruiting
NCT04516447 2026-04-07
MUIR
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 1 Recruiting
NCT07402915 2026-04-02
Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
AstraZeneca
Phase 1 Recruiting
NCT06483048 2026-03-16
MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer
Mayo Clinic
Phase 1 Recruiting
NCT03968406 2026-03-11
Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT06469281 2026-02-03
A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
Regeneron Pharmaceuticals
Phase 1 Recruiting
NCT05092373 2026-01-14
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT06856499 2026-01-09
Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer
University of Colorado, Denver
Phase 1 Recruiting
NCT04196257 2025-03-07
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
Bio-Path Holdings, Inc.
Phase 1 Recruiting
NCT04701645 2025-02-05
Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer
Brigham and Women's Hospital
Phase 1 Recruiting
NCT04811703 2024-09-19
PIPACOVA
Hospices Civils de Lyon
Phase 1 Recruiting